Clinical features and diagnosis of aspirin induced asthma

Andrzej Szczeklik, Ewa Niżankowska

Although for therapeutic reasons it has become convenient to consider asthma as a single disease entity, this clearly is not the case, with many variants occurring. From a clinical standpoint, a minimal subdivision includes atopic asthma, cough variant asthma, brittle asthma, intrinsic asthma, occupational non-IgE dependent asthma, and aspirin intolerant asthma (AIA). This last variant constitutes a clearcut clinical syndrome. It is a remarkable disease entity, this clearly is not the case, with many variants occurring. From a clinical standpoint, a minimal subdivision includes atopic asthma, cough variant asthma, brittle asthma, intrinsic asthma, occupational non-IgE dependent asthma, and aspirin intolerant asthma (AIA). This last variant constitutes a clearcut clinical syndrome. It is a remarkable syndrome.

Definition, prevalence and clinical presentation
AIA is an aggressive mucosal inflammatory disease combined with precipitation of asthma and rhinitis attacks which occurs after ingestion of aspirin and most non-steroidal anti-inflammatory drugs (NSAID). Aspirin intolerance is underdiagnosed within the asthmatic population. Based on patients’ history alone, the incidence of aspirin sensitivity in adult asthmatics is 3–5%, but this rises to 19% of consecutive adult asthmatic patients challenged with oral aspirin. Even in adult asthmatics with no history of aspirin intolerance, 9% show sensitivity to oral aspirin challenge and in those with rhinosinusitis the figure rises to 34%. The reasons for under-reporting of aspirin sensitivity may include the deliberate avoidance of NSAIDs by asthmatic patients who are aware of adverse reactions, or a lack of recognition by patients of mild NSAID induced reactions because of their delayed onset of action. Thus, in a population of 500 patients with AIA studied in the European Network of Aspirin-Induced Asthma (AIANE), 18% were unaware of aspirin intolerance before having aspirin provocation tests. This indicates that underdiagnosis of aspirin sensitivity may be due to the lack of routine aspirin challenge testing of asthmatic patients who do not report a positive history of aspirin sensitivity.

In most patients (women are affected 2.5 times more often than men), symptoms of rhinitis first occur during the third decade, often after a viral respiratory illness. Over a period of months, chronic nasal congestion, anosmia, and rhinorrhea develop. Physical examination often reveals nasal polyps. Bronchial asthma and sensitivity to aspirin develops next. After ingestion of aspirin or an NSAID, an acute asthma attack occurs within a few minutes up to three hours, usually accompanied by profuse rhinorrhea, conjunctival infection, periorbital oedema, and sometimes a scarlet flushing of the head and neck. Aspirin is a common precipitant of life threatening attacks of asthma. In a large survey, 25% of asthmatic patients requiring emergency mechanical ventilation were found to have AIA.

AIA is an aggressive mucosal inflammatory disease combined with precipitation of asthma and rhinitis attacks which occurs after ingestion of aspirin and most non-steroidal anti-inflammatory drugs (NSAID). Aspirin intolerance is underdiagnosed within the asthmatic population. Based on patients’ history alone, the incidence of aspirin sensitivity in adult asthmatics is 3–5%, but this rises to 19% of consecutive adult asthmatic patients challenged with oral aspirin. Even in adult asthmatics with no history of aspirin intolerance, 9% show sensitivity to oral aspirin challenge and in those with rhinosinusitis the figure rises to 34%. The reasons for under-reporting of aspirin sensitivity may include the deliberate avoidance of NSAIDs by asthmatic patients who are aware of adverse reactions, or a lack of recognition by patients of mild NSAID induced reactions because of their delayed onset of action. Thus, in a population of 500 patients with AIA studied in the European Network of Aspirin-Induced Asthma (AIANE), 18% were unaware of aspirin intolerance before having aspirin provocation tests. This indicates that underdiagnosis of aspirin sensitivity may be due to the lack of routine aspirin challenge testing of asthmatic patients who do not report a positive history of aspirin sensitivity.

Diagnosis of aspirin intolerance
The following clues in a patient’s history might give rise to the suspicion of AIA: (1) typical symptoms of aspirin induced respiratory reactions; (2) severe asthma accompanied by chronic nasal congestion and profuse rhinorrhea; (3) frequent development of nasal polyps; and (4) sudden severe attack of asthma requiring admission to an intensive care unit.

There is no in vitro reliable test for the diagnosis of aspirin intolerance. The diagnosis can only be established with certainty by aspirin provocation tests. There are four types of provocation tests, depending on the manner of aspirin administration: oral, bronchial (inhaled), nasal, and intravenous.

Oral challenge tests were introduced systematically into clinical practice in the early 1970s in Poland. They consisted of administration of placebo and increasing doses of aspirin during four consecutive days. The aspirin challenge test...
was considered positive if a fall in forced expiratory volume in one second (FEV₁) of more than 20% occurred, usually accompanied by bronchoconstriction and nasal symptoms. Oral challenge procedures were later introduced by some authors in the USA and in Europe. The protocols differed between the respective clinical centres in the dosage of aspirin used, the intervals between the successive doses, and the criteria for assessing the test as positive. For instance, Stevenson et al. administered placebo and increasing doses of aspirin over three consecutive days, while Dahlen and Zetterstrom administered increasing doses of aspirin during a one day long challenge procedure with very short intervals between the consecutive doses.

Inhalation (bronchial) tests for the diagnosis of aspirin intolerance were introduced into clinical practice by Bianco et al. in 1977. They were based on the administration of increasing concentrations of lysine-aspirin. In the following years the inhalation challenges were also used by Schmitz-Schumann et al., Phillips et al., and Dahlen and Zetterstrom. Inhalation of increasing concentrations of lysine-aspirin proved safer and quicker than the oral challenges, although the symptoms provoked were usually restricted to the airways.

For many years nasal challenge tests with histamine, methacholine, and allergens have been used for research purposes and in clinical studies. Nasal tests with lysine-aspirin have been used sporadically for the diagnosis of AIA. We have recently developed a diagnostic nasal lysine-aspirin challenge test using a total dose of 16 mg acetylsalicylic acid applied bilaterally into the inferior nasal conchae. The response is evaluated clinically and by anterior rhinomanometry. The test is highly sensitive and specific, but the negative results do not exclude possible intolerance to aspirin. The predictive value of a negative result was only 78.6%. A nasal provocation test carried out in line with our procedure is a simple, safe, and quick diagnostic method for the assessment of aspirin intolerance.

Some authors have used intravenous provocation tests with anti-inflammatory drugs. For instance, Martelli et al. administered indomethacin intravenously while Taniguchi et al. used lysine-aspirin intravenously.

The protocols for both oral and bronchial tests differ between various clinical centres. We recently developed similar procedures for carrying out both oral and inhalation (bronchial) tests with aspirin. The cumulative doses of aspirin in the oral challenges and of lysine-aspirin in the bronchial challenges increased in geometric progression (oral cumulative dose 500 mg aspirin, bronchial cumulative dose 182 mg). This method has made it possible to calculate the provocative dose of aspirin leading to a 20% fall in FEV₁, both during oral and bronchial challenges (PD₂₀ oral and PD₂₀ bronchial values). The oral test performed in line with our new protocol proved positive in 77.14% of patients studied, based on a 20% decrease in FEV₁. When the strong extrabranchial symptoms were also included in the criteria, the test proved positive in 88.57% of patients.

Bronchial lysine-aspirin challenge led to a decrease in FEV₁ of at least 20% in 60% of patients studied. In 17.17% of patients it proved positive when only the extrabranchial symptoms were considered. In some patients the inhaled test proved repeatedly negative, despite a positive oral challenge test. Both oral and bronchial tests had similar specificity, but the sensitivity of the oral test was somewhat higher. The inclusion of extrabranchial symptoms into the assessment criteria enhanced the diagnostic value of both procedures (fig 1).

Before carrying out provocation challenges, short acting β-mimetics should be stopped for eight hours, long acting β-mimetics for 24 hours before the tests, and theophylline 24–48 hours before testing. Antihistamines should be discontinued one week earlier. Oral and inhaled aspirin challenges should always be performed in patients with baseline FEV₁ >60% of the predicted value. As corticosteroid treatment can attenuate aspirin precipitated adverse reactions in patients with AIA, we do not usually perform any provocation tests in patients treated with oral corticosteroids in doses of more than 10 mg prednisolone daily.

Conclusions

Provocation challenges with increasing doses of aspirin or lysine-aspirin are the only reliable methods for diagnosis of aspirin intolerance. Oral challenges remain the gold standard for the diagnosis of aspirin intolerance but they may precipitate acute asthmatic reactions and therefore should be performed in specialised centres only. Bronchial challenges are safer and quicker but have somewhat less sensitivity than oral challenges. Nasal challenges are safe and may be carried out in almost all allergy centres as the routine screening procedure, even in patients with unstable asthma. It is the method of choice for confirming intolerance to aspirin when manifested only by symptoms originating in the upper respiratory tract. Patients suspected of having aspirin intolerance with negative nasal provocation tests should undergo bronchial and/or oral challenge tests with aspirin.


